Recent

% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

weightbayou 169 posts  |  Last Activity: 21 hours ago Member since: Jul 5, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "Citigroup analyst Andrew Baum expects immunotherapy revenues to reach $35 billion within 10 years, envisioning the transformation of some cancers into chronic conditions.3 A dozen new oncology treatments approved in 2012 were priced above $100,000 for 1 year of treatment." You just wait and see CLDX go much higher.

    Sentiment: Strong Buy

  • Immunotherapy treatment is the hottest area of cancer research – widely tipped to become a market worth tens of billions of dollars in annual sales – and combinations are viewed by many oncologists as the best way to use the new drugs.

    Sentiment: Strong Buy

  • weightbayou weightbayou Mar 16, 2015 2:45 PM Flag

    Thanks. This article could partially explains today's rise.

    Sentiment: Strong Buy

  • Both are already in combo trials, so it is hard to tell which one will add to revenues more down the road. Thanks in advance.

    Sentiment: Strong Buy

  • weightbayou weightbayou Mar 16, 2015 5:48 PM Flag

    There could be offers on the table now. AM is in no rush since Celldex has a goldmine pipeline.

    Sentiment: Strong Buy

  • Abstract

    The discovery and increased understanding of the complex interactions regulating the immune system have contributed to the pharmacologic activation of antitumor immunity. The activity of effector cells, such as T and NK cells, is regulated by an array of activating and attenuating receptors and ligands. Agents that target these molecules can modulate immune responses by exerting antagonistic or agonistic effects.

    Several T- or NK-cell modulators have entered clinical trials, and two have been approved for use. Ipilimumab (Yervoy®, Bristol-Myers Squibb) and nivolumab (OPDIVO, Ono Pharmaceutical Co., Ltd./Bristol-Myers Squibb) were approved for the treatment of metastatic melanoma, in March 2011 in the United States, and in July 2014 in Japan, respectively.

    2.4.2. Other members of the tumor necrosis factor superfamily

    The tumor necrosis factor (TNF) receptor family (or ‘superfamily’) contains a number of receptors which are expressed on cells of the immune system, as well as their trans-membrane ligands (Armitage, 1994). One such receptor is CD27 (also known as TNFRSF7), which is found on NK cells, as well as on T- and B-cell populations (Hendriks et al., 2000). The ligand for CD27 is CD70, which has been found on activated dendritic cells including thymic dendritic cells in humans. Interaction of CD27 with its ligand has been shown to promote differentiation of CD8+ T-cells into effector cytotoxic T cells (Brown et al., 1995). An anti-CD27 human antibody, varilumab (CDX-1127, Celldex Therapeutics) has entered clinical trials, both in hematologic malignancies (Ansell et al., 2014) and in solid tumors (Infante et al., 2014). Combinations of varilumab with BMS's anti-PD-1 monoclonal nivolumab, and with Oncothyreon's tumor-associated antigen MUC1 vaccine, ONT-10, are planned for clinical development.

    Sentiment: Strong Buy

  • weightbayou weightbayou Mar 7, 2015 9:03 PM Flag

    DB, I believe you have it right. And the good thing is that both drugs are getting into more trials.

    Sentiment: Strong Buy

  • weightbayou by weightbayou May 2, 2015 5:08 PM Flag

    "there are also a number of other Varli combo studies in the queue with other collaborators as ... cell lung cancer ... "

    .

    Sentiment: Strong Buy

  • Just mho.

    Sentiment: Strong Buy

  • Reply to

    Big Pharma may have found their "ROSETTA STONE"

    by grey3840 Mar 17, 2015 8:40 PM
    weightbayou weightbayou Mar 18, 2015 12:06 AM Flag

    Merck, Pfizer, Novartis, and others will likely get aboard the Rosetta Stone of Immunology Express.

    Sentiment: Strong Buy

  • Merck must feel left out. They need to climb aboard.

    Sentiment: Strong Buy

  • Why you say?
    1. Getting closer to a new Varli trial.
    2. Getting closer to ASCO.
    3. Oversold

    Sentiment: Strong Buy

  • See you at $50 later this year.

    Sentiment: Strong Buy

  • CLDX was about $39 back in 2012. Now, we have more trials than ever and only $27 and change for a SP.

    Sentiment: Strong Buy

  • The frenzy for cancer immunotherapy deals continued last week with two big pharma pacts. Novartis shelled out $200 million as part of a multiyear alliance with Aduro Biotech for preclinical cyclic dinucleotides. And Merck Serono paid $115 million to access Intrexon’s chimeric antigen T-cell (CART) technology.

    Aduro’s cyclic dinucleotides activate the stimulator of interferon genes, or STING, pathway, triggering a broad immune response directed at tumor cells. Novartis, which has a complementary internal program to develop small-molecule STING activators, believes the approach will boost the types of tumors that can be treated with immunotherapy.

    For Novartis, the Aduro deal adds yet another weapon to a considerable immunotherapy arsenal. The company is already committed to CART therapy, in which a patient’s own T cells are reengineered to home in on cancer, and later this year it will start clinical studies of three checkpoint inhibitors, antibodies designed to take the brakes off of the immune system.

    Sentiment: Strong Buy

  • From Forbes.

    Immune System Drugs Melt Tumors In New Study, Leading A Cancer Revolution

    The 49-year-old woman had had three melanoma growths removed from her skin, but now the disease was spreading further. A several-centimeter-sized growth under her left breast went deep into her chest wall. Some of the tissue in the tumor was dying because of lack of blood flow.

    Doctors at Memorial Sloan Kettering Cancer Center offered her an experimental combination of two drugs: Opdivo and Yervoy, both manufactured by Bristol-Myers Squibb, both among a vanguard of new medicines that boost the immune system to attack tumors. Three weeks later she came back for her second dose.

    Sentiment: Strong Buy

  • Varli is one of those drugs that has the potential of becoming a huge blockbuster. No wonder BMY got in on the action.

    Sentiment: Strong Buy

  • Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors I could not even post all the cancers it's being tested on.

    Conditions:
    Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Glioblastoma; Adult Soft Tissue Sarcoma; Adult Solid Neoplasm; Anaplastic Oligoastrocytoma; Endometrial Serous Adenocarcinoma; Estrogen Receptor Negative; Estrogen Receptor Positive; Hormone-Resistant Prostate Cancer; Male Breast Carcinoma; Metastatic Prostate Carcinoma; Recurrent Adult Brain Neoplasm; Recurrent Adult Hepatocellular Carcinoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Colon Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Lung Carcinoma; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Corpus Sarcoma; Resectable Hepatocellular Carcinoma; Stage IA Breast Cancer; Stage IA Ovarian Cancer; Stage IA Uterine Corpus Cancer; Stage IA Uterine Sarcoma; Stage IB Breast Cancer; Stage IB Ovarian Cancer; Stage IB Uterine Corpus Cancer; Stage IB Uterine Sarcoma; Stage IC Ovarian Cancer; Stage IC Uterine Sarcoma; Stage II Uterine Corpus Cancer; Stage IIA Breast Cancer; Stage IIA Lung Carcinoma; Stage IIA Ovarian Cancer; Stage IIA Uterine

    Interventions:
    Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401; Drug: Sirolimus; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study

    Sentiment: Strong Buy

  • Reply to

    New CDX-1401 Clinical Trial NCT01522820

    by ski8688 Mar 3, 2015 4:18 PM
    weightbayou weightbayou Mar 4, 2015 2:16 PM Flag

    Nice find. Maybe cdx-1401 will end up being Celldex's biggest blockbuster.

    Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
    Drug: Sirolimus
    Other: Laboratory Biomarker Analysis
    Other: Pharmacological Study

    Sentiment: Strong Buy

  • weightbayou weightbayou Mar 7, 2015 4:03 PM Flag

    Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma Conditions: Carcinoma of Unknown Primary Origin; Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Mucosal Melanoma; Ocular Melanoma With Extraocular Extension; Small Size Posterior Uveal Melanoma; Stage IIB Skin Melanoma; Stage IIB Uveal Melanoma; Stage IIC Skin Melanoma; Stage IIIA Skin Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Skin Melanoma; Stage IIIB Uveal Melanoma;

    2 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Conditions: Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma
    Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401; Drug: Poly ICLC; Drug: IDO1 Inhibitor

    3 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Chronic Myelomonocytic Leukemia
    Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Glioblastoma; Adult Soft Tissue Sarcoma; Adult Solid Neoplasm;

    4 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Glioblastoma; Adult Soft Tissue Sarcoma; Adult Solid Neoplasm; Anaplastic Oligoastrocytoma; Endometrial Serous Adenocarcinoma; Estrogen Receptor Negative; Estrogen Receptor Positive; Hormone-Resistant Prostate Cancer; Male Breast Carcinoma; Metastatic Prostate Carcinom

    Sentiment: Strong Buy

INFI
12.4725-0.3175(-2.48%)2:49 PMEDT